Viagra And Lipitor Could Be Winning Formula

A fresh scientific study has noted that if the erectile dysfunction drug Viagra made with sildenafil doesn't give a man an erection, it may just need a boost with another drug called atorvastatin or Lipitor to use the commercial name. The study consisted of 8 males with recurrent erectile dysfunction problems who initially did not react to Viagra. The eight men all reported that the Viagra functioned much better after 6 weeks of using Lipitor.

The results of the research were reported in the Journal of Sexual Medicine. The report gave credence to the hypothesis that erectile dysfunction could be a symptom of a general vascular problem such as endothelial dysfunction. The scientists said that they reckoned that if they were able to make the endothelium more healthy using statins, (to make more nitric oxide present), the endothelial dysfunction might improve and the Viagra could be more effective for the ED sufferer.

The study had twelve men who had not responded to Viagra and who also had elevated LDL cholesterol levels. The average age of participants was fifty eight. Out of the twelve men, eight were chosen to recieve the dosage of 80mg of Lipitor each day and the other four were given a placebo. After 3 months the LDL cholesterol of those recieving the Lipitor declined by 43percent from an average of 135 to 78 mg/dL. The other placebo participants noted no relevant changes. After 6 weeks the mean erectile dysfunction level of the Lipitor users had risen by almost 8 points to 18 points. (The maximum score being 30.) There was no relevant betterment of erectile function in the placebo group.

Another finding was that the 8 males all said they felt more confident about the ability to maintain an erection compared with only one male in the placebo. The results seem to suggest that there should be a  link between the amount of LDL reduced and an improvement in sexual function scores, however this was not the case. The researchers said that the fact that erectile dysfunction often appears with coronary arterial diseases and cardio/heart risks may be the justification for more research on this subject especially the lipid status of males with erectile dysfunction.

The study was not deemed to be definitive evidence for the prescription of atorvastatin to men with erectile dysfunction. It did however seem that atherosclerotic risk modification may help sexual function in men. The study that was financed by Pfizer, the makers of Viagra as well as Lipitor confirms that further research is needed in a bigger clinical trial.